INTRODUCTION AND OBJECTIVES:
Vaginal mesh sling kits for stress urinary incontinence are associated with severe complications, including mesh extrusion, urinary problems, organ perforation, and vaginal scarring. While most complications are attributable to local pathology (e.g. erosion) or device misplacement (e.g. nerve entrapment), we have observed the delayed development of severe chronic pelvic pain, despite an apparently well-placed graft. We investigated the relationship between alterations in the mesh-associated microbiota with pain symptomatology and local inflammation METHODS: Sling mesh segments were isolated from three groups of patients: 1) those with delayed-onset chronic pain, 2) those presenting mesh extrusions >1 cm, and 3) those with isolated urinary retention without pain. Explanted mesh segments were examined by culture-independent, species-specific PCR, denaturing gradient gel electrophoresis, and next-generation deep sequencing methods to detect bacterial communities on explanted mesh segments.
RESULTS: Sixty two patients were enrolled in this study. Exposed mesh segments were uniformly colonized with bacteria mirroring the vaginal microbiome. Unexpectedly, we detected bacterial species on explanted mesh from the group of patients with delayedonset pain without mesh exposure that differed greatly from the vaginal species present at explantation, suggesting an enrichment of specific pathogenic species able to survive on foreign bodies. This bacterial colonization was absent from patients without pain who underwent mesh removal to treat urinary retention.
CONCLUSIONS: We found numerous, distinct bacterial species present on the mesh removed from most subjects in group 1 that were not present in groups 2 and 3 nor in the vaginal microbiome. This suggests the need for further research to explore the relationship of these species and the associated subclinical infection and/or inflammation to delayed-onset chronic pain. METHODS: Catheterized urine specimens (CUS) were collected from 49 adult men: 29 with benign prostatic hyperplasia (BPH)/LUTS, and 20 asymptomatic males (ASM). BPH patient samples were compared to 55 CUS from age-matched women with overactive bladder (OAB). We also compared the 20 ASM to 107 CUS from agematched asymptomatic females (ASF). Bacterial growth was assessed using Expanded Quantitative Urine Culture (EQUC), which utilizes 100x more urine, additional media and environmental conditions, with double the incubation period of standard culture. Colonies grown were identified by mass spectrometry. EQUC growth and demographics were compared using chi-squared tests and Welch t-tests. Odds ratios for symptoms associated with EQUC growth were reported from multivariable logistic regression models controlling for age and hypertension (HTN) in men and age, HTN and BMI in women.
Source of
RESULTS: EQUC positivity was seen in 64.6% (135/209) of women compared to 32.7% (16/49) of men (p < 0.001). On multivariate analysis, men with BPH/LUTS were EQUC positive more often than ASM with an OR of 6.9 (95% CI 1.1-42.8, p ¼ 0.038) and women with Vol. 199, No. 4S, Supplement, Saturday, May 19, 2018 THE JOURNAL OF UROLOGY â e395 OAB were EQUC positive more often than ASF with an OR of 3.9 (95% CI 1.6-9.5, p ¼ 0.003 
PD19-04 BLADDER SENSORY MECHANISM EARLY IMPAIRMENT INDUCES DETRUSOR UNDERACTIVITY (DU) FOLLOWING BLADDER OUTLET OBSTRUCTION (BOO)
Lu ls Vale, Ana Charrua, Ant onio Avelino, Tiago Lopes, Porto, Portugal; Lori Ann Birder, Pittsburgh, PA; Francisco Cruz*, Porto, Portugal INTRODUCTION AND OBJECTIVES: DU is a contraction of reduced strength and/or duration, resulting in prolonged or incomplete bladder emptying. Estimates suggest that DU prevalence ranges from 9-23% in men <50 y, but exceeds 48% in men >70y. DU is therefore expected to be a common complication of BOO. Here, we test the hypothesis that DU occurring after BOO results from an early impairment of the bladder afferent signalling mechanism.
METHODS: BOO was obtained by creating partial urethral obstruction in female rats. After 3 and 15 days, rats were anaesthetised and cystometries were performed using saline infusion for 30 minutes at 6 ml/hour. DU and elevated voiding contractions (contr) were defined as the average contr of naïve animals AE 4 sd. This defined the cut-off as <0.2 contr/min and >1 contr/min, respectively. Saline voided was stored for ATP measurement DU bladders were then submitted to (i) intravesical infusion of 5 mg/kg ATP and (ii) serosal application of Ach (1 mM) or ATP 5 mg/kg. Sham-operated animals were used as controls. ATP was measured by bioluminescence using firefly luciferase at 37 C. RESULTS: Control rats had 0.6AE0.1 voiding cont/min. At 3 days after BOO, 63% (5/8) of rats had 1.4AE0.4 contr/min, p<0.01) while 29% (2/8) had normal frequency (0.7AE0.1 voiding contr/min) and 13% (1/8) had DU (0.0AE0.0 voiding contr/min, voiding by overflow). At 15 days, 67% (6/9) of rats had DU (0.1AE0.1 voiding contr/min, p<0.01, most of urine voided by overflow), while the remaining 33% (3/9) had more voiding contractions than controls (1.2AE0.3 cont/min, p<0.05). ATP in saline voided was 1.08E-14 mol/ml in control rats. ATP was significantly higher (1.08E-12 mol ATP/ml, p<0.01) in rats with more voiding contractions and was significantly lower (4.18E-17 mol ATP/ml, p<0.001) in rats with DU.In DU bladders, serosal application of Ach or ATP generated immediate expulsive detrusor contractions (12 cmH20 and 17 cmH20, respectively), indicating the integrity of the detrusor muscle. Intravesical application of ATP generated immediate expulsive detrusor contractions of 46 cmH20, denoting a low availability of urothelial ATP.
CONCLUSIONS: This study suggests that BOO impairs the afferent pathway before impairing the detrusor, with urothelial ATP being less available to promote bladder contraction. This mechanism may open new therapeutic options to overcome DU after BOO.
Source of Funding: None

PD19-05 THERAPEUTIC EFFECTS OF PDE9 INHIBITOR IN STORAGE AND VOIDING DYSFUNCTION IN MICE WITH SPINAL CORD INJURY (SCI)
Nobutaka Shimizu*, Osaka-Sayama, Japan; Ei-ichiro Takaoka, Takahisa Suzuki, Joonbeom Kwon, Pittsburgh, PA; Mamoru Hashimoto, Hirotsugu Uemura, Osaka-Sayama, Japan; Akihide Hirayama, Ikoma, Japan; Anthony J Kanai, William C de Groat, Naoki Yoshimura, Pittsburgh, PA INTRODUCTION AND OBJECTIVES: Phosphodiesterase (PDE) inhibitors, which can modulate cGMP or cAMP levels in tissues, such as PDE type 5 inhibitors have been used for the treatment of lower urinary tract dysfunction (LUTD). However, it remains to be elucidated whether PDE type 9 (PDE9) is involved in LUTD induced by SCI. Therefore, we investigated the effects of a PDE9 inhibitor (PDE9i) to clarify the role of PDE9 in storage and voiding dysfunction using SCI mice.
METHODS: C57BL/6N mice were used, and SCI was induced by complete transection of the Th8/9 spinal cord. Two weeks after SCI, PDE9i (5 mg/kg/day) or saline (treatment or control group, respectively) was administered daily by i.p. injection for 14days in. Four weeks after SCI, mice were evaluated using cystometry (CMG) under an awake condition. L6 dorsal root ganglia (DRG), urethral, bladder muscle and mucosal specimens were obtained from PDE9i and salinetreated SCI mice as well as saline-treated normal (spinal intact) mice to evaluate the levels of PDE9, TRPV1 and TNFa transcripts by realtime PCR RESULTS: Compared to saline-treated SCI mice, non-voiding contractions during bladder filling were significantly reduced (Figure 1) , and voiding efficiency was significantly improved in PDE9i-treated SCI mice (Figure 2 ). The levels of TRPV1 mRNA in DRG and bladder muscle were increased in SCI mice compared to spinal intact mice, and significantly decreased after PDE9i treatment in SCI mice. The TNFa mRNA levels in urethra, bladder muscle and mucosa were increased in SCI mice compared to spinal intact mice, and significantly decreased after PDE9i treatment in SCI mice. PDE9 transcripts were identified in L6 DRG and bladder tissues.
CONCLUSIONS: PDE9 inhibition improved SCI-induced detrusor overactivity and inefficient voiding, along with significant reductions in C-fiber afferent receptors such as TRPV1 and proinflammatory cytokines such as TNFa in mice. Thus, PDE9 could be a therapeutic target for storage and voiding LUTD after SCI.
